UnitedHealth Group shares dropped 5.2% in morning trading on Wednesday, hitting an intraday low of $378.08 after opening near $405. The decline extends a broader pullback from the stock’s 52-week high of $461.62 reached during the summer.
Several factors are weighing on UNH. The quarterly dividend of $2.32 per share has a record date of September 14, and the payment date is September 22, prompting dividend-capture traders to exit positions ahead of the ex-dividend date. Additionally, stronger-than-expected August nonfarm payrolls data has raised expectations for further Federal Reserve rate tightening, which historically pressures large-cap managed-care names through higher discount rates. The broader market was also lower, with the S&P 500 down 0.3% and the Dow Jones down 0.7%.
Despite the slide, UnitedHealth’s fundamentals remain solid. Q2 2026 EPS came in at $6.38, beating the $4.94 consensus estimate, while revenue reached $112.03 billion versus expectations of $110.81 billion. Management raised full-year adjusted EPS guidance to $19.50–$20.00, and net earnings were up about 21% year-over-year.
Analyst sentiment remains broadly positive. Oppenheimer has a $500 price target, JPMorgan $516, and Mizuho $493, with consensus at $456.56 and a Moderate Buy rating. Institutional ownership sits at 87.86%.
In a separate development, UnitedHealth confirmed the sale of a partial stake in its Optum Health Florida primary-care clinic network, including WellMed operations, to private equity firm TPG. The deal allows UNH to bring in strategic growth capital while retaining an equity interest in the regional clinic footprint. The TPG partnership is expected to help fund roughly 15 new clinic locations annually, de-risk Optum’s balance sheet against Medicare Advantage margin pressure, and free up cash for debt reduction, buybacks, or higher-margin OptumRx and Optum Insight investments.
Wall Street currently rates UnitedHealth shares at Overweight with a mean price target near $480, implying more than 20% upside from current levels. CEO Patrick Conway sold 1,169 shares at $390 on August 21, reducing his stake by 7.09%.
